BG104533A - Ген за психоматични разстройства - Google Patents

Ген за психоматични разстройства Download PDF

Info

Publication number: BG104533A
Authority: BG; Bulgaria
Prior art keywords: disorder; dna; sequence; yac; gene
Prior art date: 1997-12-18

Application number

BG104533A

Other languages

Bulgarian (bg)

English (en)

Inventor

Peter Raeymaekers

Broeckhoven Christine Van

Jurgen Del-Favero

Original Assignee

Vlaams Interuniversitair Instituut Voor Biotechnologie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-18

Filing date

2000-06-15

Publication date

2001-04-30

2000-06-15 Application filed by Vlaams Interuniversitair Instituut Voor Biotechnologie filed Critical Vlaams Interuniversitair Instituut Voor Biotechnologie

2001-04-30 Publication of BG104533A publication Critical patent/BG104533A/bg

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 133
208000019022 Mood disease Diseases 0.000 title abstract description 6
238000000034 method Methods 0.000 claims abstract description 84
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 55
241000282414 Homo sapiens Species 0.000 claims abstract description 35
239000012634 fragment Substances 0.000 claims abstract description 18
210000003917 human chromosome Anatomy 0.000 claims abstract description 16
108020004414 DNA Proteins 0.000 claims description 74
210000000349 chromosome Anatomy 0.000 claims description 69
208000012545 Psychophysiologic disease Diseases 0.000 claims description 62
239000002773 nucleotide Substances 0.000 claims description 41
125000003729 nucleotide group Chemical group 0.000 claims description 41
102000004169 proteins and genes Human genes 0.000 claims description 29
239000013598 vector Substances 0.000 claims description 28
235000018102 proteins Nutrition 0.000 claims description 27
108020004707 nucleic acids Proteins 0.000 claims description 24
102000039446 nucleic acids Human genes 0.000 claims description 24
150000007523 nucleic acids Chemical class 0.000 claims description 24
210000004027 cell Anatomy 0.000 claims description 22
108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
239000002299 complementary DNA Substances 0.000 claims description 18
230000014509 gene expression Effects 0.000 claims description 18
239000000523 sample Substances 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 16
230000003321 amplification Effects 0.000 claims description 13
238000003199 nucleic acid amplification method Methods 0.000 claims description 13
108091029523 CpG island Proteins 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
210000004962 mammalian cell Anatomy 0.000 claims description 7
239000013612 plasmid Substances 0.000 claims description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
108091026890 Coding region Proteins 0.000 claims description 6
238000013467 fragmentation Methods 0.000 claims description 6
238000006062 fragmentation reaction Methods 0.000 claims description 6
230000035772 mutation Effects 0.000 claims description 6
108700024394 Exon Proteins 0.000 claims description 5
239000013601 cosmid vector Substances 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 5
238000009396 hybridization Methods 0.000 claims description 5
108020004999 messenger RNA Proteins 0.000 claims description 5
238000013518 transcription Methods 0.000 claims description 5
230000035897 transcription Effects 0.000 claims description 5
108700008625 Reporter Genes Proteins 0.000 claims description 4
230000000295 complement effect Effects 0.000 claims description 4
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 4
210000001519 tissue Anatomy 0.000 claims description 4
238000000636 Northern blotting Methods 0.000 claims description 3
108700019146 Transgenes Proteins 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 2
108090000144 Human Proteins Proteins 0.000 claims description 2
102000003839 Human Proteins Human genes 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
235000004554 glutamine Nutrition 0.000 claims description 2
208000022821 personality disease Diseases 0.000 claims description 2
208000020016 psychiatric disease Diseases 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
238000011144 upstream manufacturing Methods 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims 4
239000003112 inhibitor Substances 0.000 claims 4
108020003215 DNA Probes Proteins 0.000 claims 2
239000003298 DNA probe Substances 0.000 claims 2
108700039691 Genetic Promoter Regions Proteins 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000003275 alpha amino acid group Chemical group 0.000 claims 1
210000003527 eukaryotic cell Anatomy 0.000 claims 1
230000007614 genetic variation Effects 0.000 claims 1
230000001575 pathological effect Effects 0.000 claims 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 124
208000020925 Bipolar disease Diseases 0.000 description 22
108091092878 Microsatellite Proteins 0.000 description 22
238000004458 analytical method Methods 0.000 description 21
238000013507 mapping Methods 0.000 description 19
230000002068 genetic effect Effects 0.000 description 18
101000661600 Homo sapiens Steryl-sulfatase Proteins 0.000 description 9
102000054766 genetic haplotypes Human genes 0.000 description 9
102000054458 human STS Human genes 0.000 description 9
239000003550 marker Substances 0.000 description 9
150000001413 amino acids Chemical group 0.000 description 6
238000005204 segregation Methods 0.000 description 6
238000001228 spectrum Methods 0.000 description 6
206010026749 Mania Diseases 0.000 description 5
238000012360 testing method Methods 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000002759 chromosomal effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000000499 gel Substances 0.000 description 4
208000024714 major depressive disease Diseases 0.000 description 4
230000005855 radiation Effects 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000004807 localization Effects 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000007017 scission Effects 0.000 description 3
108091035539 telomere Proteins 0.000 description 3
210000003411 telomere Anatomy 0.000 description 3
102000055501 telomere Human genes 0.000 description 3
230000009466 transformation Effects 0.000 description 3
108700028369 Alleles Proteins 0.000 description 2
101100351299 Caenorhabditis elegans pdf-1 gene Proteins 0.000 description 2
206010068051 Chimerism Diseases 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
206010021030 Hypomania Diseases 0.000 description 2
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
201000000760 cerebral cavernous malformation Diseases 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000003205 genotyping method Methods 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000004630 mental health Effects 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
238000003906 pulsed field gel electrophoresis Methods 0.000 description 2
238000007670 refining Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
108091023043 Alu Element Proteins 0.000 description 1
108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101150014715 CAP2 gene Proteins 0.000 description 1
101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241001301450 Crocidium multicaule Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
244000148064 Enicostema verticillatum Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101150008942 J gene Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
229910009891 LiAc Inorganic materials 0.000 description 1
101001097860 Lithospermum erythrorhizon Phenylalanine ammonia-lyase 1 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
241000714209 Norwalk virus Species 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
208000026725 cyclothymic disease Diseases 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000007943 implant Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pathology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BG104533A 1997-12-18 2000-06-15 Ген за психоматични разстройства BG104533A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9726804.9A GB9726804D0 (en)	1997-12-18	1997-12-18	Mood disorder gene
PCT/EP1998/008543 WO1999032643A2 (en)	1997-12-18	1998-12-17	Mood disorder gene

Publications (1)

Publication Number	Publication Date
BG104533A true BG104533A (bg)	2001-04-30

Family

ID=10823856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104533A BG104533A (bg)	1997-12-18	2000-06-15	Ген за психоматични разстройства

Country Status (13)

Country	Link
EP (1)	EP1038015B1 (de)
JP (1)	JP2001526897A (de)
AT (1)	ATE329044T1 (de)
AU (1)	AU2514999A (de)
BG (1)	BG104533A (de)
CA (1)	CA2314437A1 (de)
DE (1)	DE69834831T2 (de)
ES (1)	ES2262256T3 (de)
GB (1)	GB9726804D0 (de)
HU (1)	HUP0100409A3 (de)
PL (1)	PL341814A1 (de)
TR (1)	TR200001965T2 (de)
WO (1)	WO1999032643A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2407124C (en) *	2000-04-25	2010-09-28	Spectrumedix Corporation	Denaturant-free electrophoresis of biological molecules under high temperature conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7089896A (en) *	1995-09-23	1997-04-09	Medical Research Council	Screening for disorders of serotonergic dysfunction
FR2741088B1 (fr) *	1995-11-10	1998-01-30	Centre Nat Rech Scient	Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes
JP2001510322A (ja) *	1996-03-29	2001-07-31	ザリージェンツオブザユニバーシティオブカリフォルニア	１８番染色体長腕（１８ｑ）上のマーカーに相関する両極性気分障害の治療法

1997
- 1997-12-18 GB GBGB9726804.9A patent/GB9726804D0/en not_active Ceased
1998
- 1998-12-17 HU HU0100409A patent/HUP0100409A3/hu unknown
- 1998-12-17 PL PL98341814A patent/PL341814A1/xx not_active Application Discontinuation
- 1998-12-17 TR TR2000/01965T patent/TR200001965T2/xx unknown
- 1998-12-17 AU AU25149/99A patent/AU2514999A/en not_active Abandoned
- 1998-12-17 CA CA002314437A patent/CA2314437A1/en not_active Abandoned
- 1998-12-17 WO PCT/EP1998/008543 patent/WO1999032643A2/en not_active Ceased
- 1998-12-17 JP JP2000525561A patent/JP2001526897A/ja active Pending
- 1998-12-17 AT AT98966865T patent/ATE329044T1/de not_active IP Right Cessation
- 1998-12-17 EP EP98966865A patent/EP1038015B1/de not_active Expired - Lifetime
- 1998-12-17 DE DE69834831T patent/DE69834831T2/de not_active Expired - Fee Related
- 1998-12-17 ES ES98966865T patent/ES2262256T3/es not_active Expired - Lifetime
2000
- 2000-06-15 BG BG104533A patent/BG104533A/bg unknown

Also Published As

Publication number	Publication date
PL341814A1 (en)	2001-05-07
GB9726804D0 (en)	1998-02-18
EP1038015A2 (de)	2000-09-27
AU2514999A (en)	1999-07-12
WO1999032643A2 (en)	1999-07-01
HUP0100409A3 (en)	2003-09-29
TR200001965T2 (tr)	2000-12-21
WO1999032643A3 (en)	1999-10-21
CA2314437A1 (en)	1999-07-01
ATE329044T1 (de)	2006-06-15
ES2262256T3 (es)	2006-11-16
JP2001526897A (ja)	2001-12-25
DE69834831T2 (de)	2007-02-01
HUP0100409A2 (hu)	2001-06-28
EP1038015B1 (de)	2006-06-07
DE69834831D1 (de)	2006-07-20

Publication	Publication Date	Title
Flavigny et al.	1998	Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy
JP4723550B2 (ja)	2011-07-13	生存運動ニューロン（ｓｍｎ）遺伝子；脊髄筋萎縮
Hes et al.	2000	Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene
Jeschke et al.	1998	A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes
KR20000062427A (ko)	2000-10-25	질병의 대규모 유전자형 식별방법 및 척수소뇌성 운동실조 타입 6의 진단방법
US6566064B1 (en)	2003-05-20	Method for anticipating sensitivity to medicine for osteoporosis
AU693562B2 (en)	1998-07-02	Method and probes for detecting markers bound to the locus of child spinal muscular atrophies
Growney et al.	2000	Evolutionary divergence of the mouse and human Lgn1/SMA repeat structures
Kanters et al.	1998	Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome
BG104533A (bg)	2001-04-30	Ген за психоматични разстройства
AU2004249919B2 (en)	2009-08-13	Methods for the diagnosis and prognosis of Alzheimer's disease
JP2006121961A (ja)	2006-05-18	顎骨骨幹異形成症ｇｄｄの原因遺伝子ｇｄｄ１とその用途
JP4776841B2 (ja)	2011-09-21	脈管形成分野におけるＫｒｉｔ１遺伝子の使用
Moric-Janiszewska et al.	2004	Mutational screening of SCN5A linked disorders in Polish patients and their family members
JP2000316577A (ja)	2000-11-21	成人発症ｉｉ型シトルリン血症の診断方法
CN115927354B (zh)	2024-02-20	一种sh3tc2基因致病突变体及其在制备腓骨肌萎缩症4c型诊断试剂盒中的应用
JP4048555B2 (ja)	2008-02-20	骨粗鬆症薬剤感受性予測方法
US7803538B2 (en)	2010-09-28	Method for detecting Alzheimer's disease
JP3684921B2 (ja)	2005-08-17	骨粗鬆症薬剤感受性予測方法
CZ20002282A3 (cs)	2000-11-15	Gen asociovaný s poruchou nálady, jeho použití a způsob identifikace
Ging	2020	Investigating the Role of Modifiers in Trinucleotide Repeat Diseases
CN116004799A (zh)	2023-04-25	Crtap致病突变体及在制备脆骨症ⅶ型诊断试剂盒中的应用
Goossens	2001	Cloning of candidate genes for bipolar disorder starting from expanded trinucleotide repeats
Esterhuizen	2010	Duchenne muscular dystrophy: mutation profiling in view of the emerging gene-based therapies
HK1090392B (en)	2014-08-01	Methods for the diagnosis and prognosis of alzheimer's disease